Minerva Neurosciences Inc (NERV)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Minerva Neurosciences Inc chart...

About the Company

minerva neurosciences, inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. its lead product candidate is roluperidone, which is in phase iii clinical trial, a compound for the treatment of schizophrenia. the company is also developing seltorexant that has completed phase iib clinical trial for treating insomnia and major depressive disorders; and min-301, which is in pre-clinical trial, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of parkinson's disease. minerva neurosciences, inc. has a license agreement with mitsubishi tanabe pharma corporation for the development and commercialization of the roluperidone worldwide, excluding asia; and co-development and license agreement with janssen pharmaceutica, n.v. for the development of seltorexant. the company was formerly known as cyrenaic pharmaceuticals, inc. and changed its

$41M

Total Revenue

8

Employees

$20M

Market Capitalization

-0.60

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $NERV News

Minerva Neurosciences: Q4 Earnings Snapshot

25d ago, source: The Washington Post

BURLINGTON, Mass. — BURLINGTON, Mass. — Minerva Neurosciences Inc. (NERV) on Thursday reported a loss of $9 million in its fourth quarter. The Burlington, Massachusetts-based company said it ...

Hold Rating on Minerva Neurosciences Amid FDA Setbacks and Financial Constraints

20d ago, source: Business Insider

Douglas Tsao, an analyst from H.C. Wainwright, maintained the Hold rating on Minerva Neurosciences (NERV – Research Report). The associated price target is $11.00. Douglas Tsao has given his ...

Minerva Neurosciences, Inc: Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates

25d ago, source: Finanznachrichten

About Minerva Neurosciences Minerva Neurosciences, Inc. Forward-Looking Safe Harbor Statement This press release contains forward-looking statements which are subject to the safe harbor provisions ...

Minerva Neurosciences Inc NERV

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Minerva Neurosciences Inc NERV

18d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Minerva Neurosciences Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Minerva Neurosciences Inc (NERV)

25d ago, source: Investing

Minerva Neurosciences (NASDAQ:NERV), Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...